Seeking Alpha: NuVasive Riding A New Wave Of Optimism

Sell-side analysts still seem to be nervous about the near-term future of the spine market, but investors haven't let that scare them away from NuVasive (NUVA). With new products and a focused OUS strategy re-accelerating growth and management laying out some bold ambitions for the next five years, these shares have more than doubled over the past year. This move doesn't have the shares looking particularly cheap these days, but if expectations for ortho M&A stay in place and NuVasive continues to take share from large rivals like Johnson & Johnson (JNJ) and Medtronic (MDT), I don't think the Street will get all that concerned about valuation.



Follow this link to continue:
NuVasive Riding A New Wave Of Optimism